Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$34.69

0.1625 (0.47%)

13:03
10/13/17
10/13
13:03
10/13/17
13:03

AstraZeneca says CHMP adopts positive opinion for Faslodex to expand use

AstraZeneca announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Faslodex that will expand its use to include combination therapy with palbociclib. The combination use is for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. The CHMP opinion is based on data from the Phase III PALOMA-3 trial. The combination of fulvestrant 500 mg and palbociclib 125 mg resulted in a 4.9 month progression-free survival improvement over fulvestrant and placebo in women with HR+, HER2- advanced breast cancer whose disease had progressed after endocrine therapy. Improvement in PFS was seen regardless of menopausal status.2 The most-commonly reported adverse events in fulvestrant plus palbociclib compared to fulvestrant plus placebo were neutropenia, leukopenia and infections.

  • 15

    Oct

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

AZN AstraZeneca
$34.69

0.1625 (0.47%)

09/21/17
UBSW
09/21/17
NO CHANGE
Target $500
UBSW
Buy
Regeneron price target lowered to $500 from $535 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.
09/22/17
BERN
09/22/17
UPGRADE
BERN
Outperform
AstraZeneca upgraded to Outperform from Market Perform at Bernstein
Bernstein analyst Tim Anderson upgraded AstraZeneca, saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. However, he adds that that the company "has one of the fullest Phase 3 pipelines in the group." Additionally, he is upbeat on the changes it is making and believes that its financial results will improve more quickly than those of its peers. Finally, he believes that it could become a takeover target. Target GBP5,780.
09/22/17
09/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Overweight from Equal Weight at Barclays with analyst Brandon Oglenski saying the company appears to have all the attributes of a "value compounding opportunity" for equity investors. 2. Mindbody (MB) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brent Bracelin saying elevated churn risk from the company's model transition to higher-value subscribers is now discounted into the valuation. 3. Enviva (EVA) upgraded to Buy from Neutral at Citi with analyst Ryan Levine saying he likes the risk/reward at current levels and believes Enviva is well positioned in the next 12-18 months. 4. PSEG (PEG) upgraded to Overweight from Equal Weight at Barclays with analyst Gregg Orrill saying the company could be the industry's largest beneficiary of potential near-term policy initiatives. 5. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Bernstein with analyst Tim Anderson saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/25/17
RHCO
09/25/17
NO CHANGE
Target $19
RHCO
Buy
NewLink collaboration with AstraZeneca a validation, says SunTrust
SunTrust analyst Peter Lawson said NewLink Genetics' (NLNK) newly-announced collaboration with AstraZeneca (AZN) is the first "big pharma" partnership for NewLink's lead IDO pathway inhibitor. The deal adds external validation to an asset that is "trading at a fraction" of Incyte's IDO, said Lawson, who keeps a Buy rating and $19 price target on NewLink shares.

TODAY'S FREE FLY STORIES

HOC

Holly

03:35
02/22/18
02/22
03:35
02/22/18
03:35
Upgrade
Holly rating change  »

Holly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$54.93

1.22 (2.27%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Clovis rating change  »

Clovis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HST

Host Hotels

$19.22

-0.29 (-1.49%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SLCA

U.S. Silica

$25.15

-5.6 (-18.21%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
U.S. Silica rating change  »

U.S. Silica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

TEO

Telecom Argentina

$34.09

-0.19 (-0.55%)

03:32
02/22/18
02/22
03:32
02/22/18
03:32
Downgrade
Telecom Argentina rating change  »

Telecom Argentina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

03:30
02/22/18
02/22
03:30
02/22/18
03:30
General news
FX Action: USD-CAD clocked a two-month high »

FX Action: USD-CAD…

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$80.25

3.79 (4.96%)

03:25
02/22/18
02/22
03:25
02/22/18
03:25
Upgrade
MSA Safety rating change  »

MSA Safety upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

02:50
02/22/18
02/22
02:50
02/22/18
02:50
General news
FX Update: The dollar has continued to mostly trade firmer »

FX Update: The dollar…

02:15
02/22/18
02/22
02:15
02/22/18
02:15
General news
Asian Market Summary: »

Asian Market Summary:…

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.